BCRX Financial Facts

Collaborative and other research and development: 5.16M
Product sales: 5.7M
See Full Income Statement

Restricted cash: 1.62M
Total current liabilities: 64.44M
See Full Balance Sheet

BioCryst Pharmaceuticals, Inc. (BCRX) Earnings

  |   Expand Research on BCRX
Next EPS Date 2/18/16 *Est. EPS Growth Rate -66.7% *Last Qtr.
Average EPS % Beat Rate +42.9% Revenue Growth Rate +243.8% *Last Qtr.
Average % Move 1-Wk after EPS -2.6% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/5/15 Q315 -$0.20-$0.20 $0.00$11M$6.77M N/A Details
8/7/15 Q215 $0.07-$0.22 +$0.29$25.8M$7.1M N/A Details
5/8/15 Q115 -$0.21-$0.25 +$0.04$6.8M$4.3M N/A Details
2/18/15 Q414 -$0.16-$0.21 +$0.05$5.4M$3.64M N/A Details
11/6/14 Q314 -$0.12-$0.20 +$0.08$3.2M$2.11M N/A Details
8/5/14 Q214 -$0.23-$0.19 -$0.04$1.5M$2.32M N/A Details
5/8/14 Q114 -$0.17-$0.17 $0.00N/A$3.34M N/A Details
2/26/14 Q413 -$0.09-$0.08 -$0.01$10.6M$8.81M N/A Details